@article{7d17b599fe75470e810243b101691fd1,
title = "New cancers after autotransplantations for multiple myeloma",
abstract = "We describe baseline incidence and risk factors for new cancers in 4161 persons receiving autotransplants for multiple myeloma in the United States from 1990 to 2010. Observed incidence of invasive new cancers was compared with expected incidence relative to the US population. The cohort represented 13,387 person-years at-risk. In total, 163 new cancers were observed, for a crude incidence rate of 1.2 new cancers per 100 person-years and cumulative incidences of 2.6% (95% confidence interval [CI], 2.09 to 3.17), 4.2% (95% CI, 3.49 to 5.00), and 6.1% (95% CI, 5.08 to 7.24) at 3, 5, and 7years, respectively. The incidence of new cancers in the autotransplantation cohort was similar to age-, race-, and gender-adjusted comparison subjects with an observed/expected (O/E) ratio of 1.00 (99% CI, .81 to 1.22). However, acute myeloid leukemia and melanoma were observed at higher than expected rates with O/E ratios of 5.19 (99% CI, 1.67 to 12.04; P=0004), and 3.58 (99% CI, 1.82 to 6.29; P < .0001), respectively. Obesity, older age, and male gender were associated with increased risks of new cancers in multivariate analyses. This large data set provides a baseline for comparison and defines the histologic type specific risk for new cancers in patients with MM receiving postautotransplantation therapies, such as maintenance.",
keywords = "Myeloma, Second cancer, Transplantation",
author = "Anuj Mahindra and Girindra Raval and Paulette Mehta and Ruta Brazauskas and Zhang, {Mei Jie} and Xiaobo Zhong and Bird, {Jennifer M.} and Freytes, {C{\'e}sar O.} and Hale, {Gregory A.} and Roger Herzig and Holmberg, {Leona A.} and Kamble, {Rammurti T.} and Shaji Kumar and Lazarus, {Hillard M.} and Majhail, {Navneet S.} and Marks, {David I.} and Moreb, {Jan S.} and Richard Olsson and Wael Saber and Savani, {Bipin N.} and Schiller, {Gary J.} and Jason Tay and Vogl, {Dan T.} and Waller, {Edmund K.} and Wiernik, {Peter H.} and Baldeep Wirk and Sagar Lonial and Krishnan, {Amrita Y.} and Angela Dispenzieri and Brandenburg, {Nancy A.} and Gale, {Robert Peter} and Hari, {Parameswaran N.}",
note = "Funding Information: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute , the National Heart, Lung, and Blood Institute and the National Institute of Allergy and Infectious Diseases ; a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI ; a contract HHSH250201200016C with Health Resources and Services Administration; 2 grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research ; and grants from Actinium Pharmaceuticals ; Allos Therapeutics, Inc. ; Amgen ; anonymous donation to the Medical College of Wisconsin; Ariad; Be The Match Foundation ; Blue Cross and Blue Shield Association ; Celgene Corporation ; Chimerix, Inc. ; Fred Hutchinson Cancer Research Center ; Fresenius-Biotech North America, Inc. ; Gamida Cell Teva Joint Venture Ltd. ; Genentech, Inc. ; Gentium SpA ; Genzyme Corporation ; GlaxoSmithKline ; Health Research, Inc. ; Roswell Park Cancer Institute ; HistoGenetics ; Incyte Corporation ; Jeff Gordon Children's Foundation ; Kiadis Pharma ; The Leukemia & Lymphoma Society ; Medac GmbH ; The Medical College of Wisconsin ; Merck & Co., Inc. ; Millennium: The Takeda Oncology Co .; Milliman USA, Inc. ; Miltenyi Biotec ; National Marrow Donor Program ; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc. ; Osiris Therapeutics ; Otsuka America Pharmaceutical, Inc. ; Perkin Elmer, Inc. ; Remedy Informatics; Sanofi US ; Seattle Genetics ; Sigma-Tau Pharmaceuticals ; Soligenix, Inc. ; St. Baldrick's Foundation ; StemCyte , A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc. ; Swedish Orphan Biovitrum ; Tarix Pharmaceuticals ; Terumo BCT ; Teva Neuroscience, Inc. ; Therakos ; University of Minnesota ; University of Utah ; and WellPoint The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration or any other agency of the US Government. Additional support for this study was provided by Celgene Corporation. ",
year = "2015",
month = apr,
day = "1",
doi = "10.1016/j.bbmt.2014.12.028",
language = "English (US)",
volume = "21",
pages = "738--745",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",
}